Market MomentumOrganic growth should accelerate, and margins expand, benefiting from improving market momentum and product launches.
Organic GrowthEquasens had a strong Q1 with 5.9% organic growth, which should help the company regain some of the lost confidence from the investment community.
UndervaluationEquasens is materially undervalued given that its momentum is set to improve in 2025, with a potential for re-rating driven by improved end-customer health, new product launches, regulatory tailwinds, and easier comparison basis.